

GLUCONORM-Z XR

Metformin 500mg (Extended Release) +
Gliclazide 60mg (Extended Release)

SIMPLE. SAFE. SECURE.

**OD Dose
Advantage**

1.9% in HbA1c with Progressive Up Titration^{1*}

GUIDE study: 50% Hypoglycemia Risk Compared to Glimepiride²

STENO-2 Study: Life Span with 8.1 Years Free from Ischemic Heart Disease³

*Gliclazide MR 60 mg titrated upto 120 mg showed HbA1c reduction by 1.9% (9.2%-7.3%) at month 6.

References:

1. Borgharkar SS, Das SS. Real-world evidence of glycemic control among patients with type 2 diabetes mellitus in India: the TIGHT study. *BMJ Open Diabetes Res Care*. 2019 Jul 4;7(1):e000654.
2. Wangnoo S, Shunmugavelu M, Reddy SVB, Negalur V, Godbole S, Kdhandhana V. Role of Gliclazide in safely navigating type 2 diabetes mellitus patients towards euglycemia: Expert opinion from India. *Endocrine and Metabolic Science*. 2021 Sept;4:100102.
3. Kalra, S., et al. The Position of Gliclazide in the Evolving Landscapes and Disease Continuum of T2DM: A Collaborative Delphi Survey-Based Consensus from India. *Diabetes Ther* 12, 679–695 (2021). <https://doi.org/10.1007/s13300-021-01002-4>

From
SYNOX
A Division of LUPIN

Also Available

GLUCONORM-Z

Metformin 500mg + Gliclazide 80mg